Inotuzumab therapy resulted in molecular remission of relapsed/resistant B-cell acute lymphoblastic leukemia with BCR::ABL1 Lys404Glu mutation.

ABSTRACT: The Philadelphia positive acute lymphoblastic leukemia (ALL BCR::ABL1 positive) is characterized by the presence of the t(9;22)(q34;q11) resulting in the formation of the BCR::ABL1 fusion, constant high cellular BCR-ABL1 tyrosine kinase activity, abnormal lymphoid cell proliferation and genetic instability of leukemic cells. Recently, great progress has been made due to the incorporation of tyrosine kinase inhibitors (TKI's) into the treatment algorithms. Despite this, a significant number of patients experienced therapy resistance mainly due to disease evolution and/or acquisition of TKI resistant BCR::ABL1 mutation(s). Herein, we report the therapy outcome in a 65 year old woman with high-risk BCR::ABL1 positive ALL treated with the PALG ALL7 (including imatinib, IM) protocol, who obtain

SUBMITTER: Lewandowski K 

PROVIDER: S-EPMC12334529 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature